A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects